1-10 of 10
J. Newton
Close
Sort by
Journal Articles

Assessment of Eculizumab and C5 Levels in PNH Treatment: Molar Ratio of Eculizumab to C5 Level Effectively Predicts Ongoing Dosage Changes in a Cohort of 50 Patients Treated with Eculizumab

Darren J Newton, PhD, Claire E McKinley, BSc, Alonso Ricardo, PhD, Michelle D Hoarty, PhD, Louise Arnold, Kathryn Riley, Nicola Copeland, Talha Munir, Morag Griffin, Anita Hill, MBChB (Hons), PhD, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3484.
https://doi.org/10.1182/blood.V130.Suppl_1.3484.3484
Published: 2017
Journal Articles

Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome

Claire E McKinley, BSc, Stephen John Richards, PhD FRCPath, Talha Munir, Morag Griffin, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Louise Arnold, Kathryn Riley, Nicola Copeland, Darren J Newton, PhD, Anita Hill, MBChB (Hons), PhD, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3471.
https://doi.org/10.1182/blood.V130.Suppl_1.3471.3471
Published: 2017
Journal Articles

Fibrinogen and Clot Structure Is Affected By Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria

Fraser Macrae, BSc, PhD, Polly Bowman, Emma Linton, Barnaby Peacock-Young, Deborah Clarke, MSc, Darren J Newton, PhD, Claire E McKinley, BSc, Kathryn Riley, Nicola Copeland, Louise Arnold, Morag Griffin, Talha Munir, Peter Hillmen, MBChB, PhD, Stephen John Richards, PhD FRCPath, Robert Ariens, BSc, PhD, Anita Hill, MBChB (Hons), PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 462.
https://doi.org/10.1182/blood.V130.Suppl_1.462.462
Published: 2017
Journal Articles

Minimal residual disease is an independent predictor for 10-year survival in CLL

Clinical Trials & Observations Brief Report
Marwan Kwok, Andy C. Rawstron, Abraham Varghese, Paul A. S. Evans, Sheila J. M. O’Connor, Chi Doughty, Darren J. Newton, Paul Moreton, Peter Hillmen
Journal: Blood
Blood (2016) 128 (24): 2770–2773.
https://doi.org/10.1182/blood-2016-05-714162
Published: 2016
Includes: Supplemental data
Journal Articles

“Red Cell Complement Loading In PNH Patients On Eculizumab Is Associated With a C3 Polymorphism Which Influences C3 Function, Predicts For Increased Extravascular Hemolysis and Provides a Rationale For C3 Inhibition.”

Praveen Kaudlay, MBBS, MRCP, Haiying Hua, MD, Guansheng He, MD, Darren J Newton, PhD, Abraham M Varghese, MB ChB, Talha Munir, MBBS, MRCP, FRCPath, Anita Hill, MBChB, PhD, Richard J Kelly, MBChB, Stephen John Richards, PhD, Peter Hillmen, MB ChB, PhD
Journal: Blood
Blood (2013) 122 (21): 2466.
https://doi.org/10.1182/blood.V122.21.2466.2466
Published: 2013
Journal Articles

What Numbers Don't Say: Immunogenetic Evidence Shows That High-Count MBL Resembles Rai 0 CLL While Low-Count MBL Does Not.

Anna Vardi, Antonis Dagklis, Lydia Scarfò, Diane F. Jelinek, PhD, Darren J Newton, Chi Doughty, PhD, Julia Almeida, Arancha Rodriguez-Caballero, Sallie D. Allgood, MS, Mark C. Lanasa, MD, PhD, Agostino Cortelezzi, MD, Ester M Orlandi, Silvio Veronese, Marco Montillo, MD, Andy Rawstron, PhD, Tait D. Shanafelt, MD, Alberto Orfao, Kostas Stamatopoulos, Paolo Ghia
Journal: Blood
Blood (2012) 120 (21): 2883.
https://doi.org/10.1182/blood.V120.21.2883.2883
Published: 2012
Journal Articles

Aberrant Expression of Neuronal Receptors in CLL: Potential Targets with Therapeutic Implications

Abraham M Varghese, Andy Rawstron, PhD, Gina M Doody, PhD, Darren J Newton, Reuben Tooze, PhD, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2012) 120 (21): 3899.
https://doi.org/10.1182/blood.V120.21.3899.3899
Published: 2012
Journal Articles

Differential Protein Expression in MBL and CLL: LAIR1 Is a Powerful Surface Marker for Identifying Cases with Adverse Cellular Features.

Andy C Rawstron, BSc, PhD, Darren J Newton, Ruth M. de Tute, Jane Shingles, Fiona L Bennett, Paul A.S. Evans, Sheila J.M. O’Connor, Andrew S Jack, Peter Hillmen
Journal: Blood
Blood (2008) 112 (11): 2076.
https://doi.org/10.1182/blood.V112.11.2076.2076
Published: 2008
Journal Articles

Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse

K. Tobal, J. Newton, M. Macheta, J. Chang, G. Morgenstern, P. A. S. Evans, G. Morgan, G. S. Lucas, J. A. Liu Yin
Journal: Blood
Blood (2000) 95 (3): 815–819.
https://doi.org/10.1182/blood.V95.3.815.003k30_815_819
Published: 2000
Journal Articles

Human serum megakaryocyte colony-stimulating activity appears to be distinct from interleukin-3, granulocyte-macrophage colony-stimulating factor, and lymphocyte-conditioned medium

EM Mazur, JL Cohen, J Newton, P Sohl, A Narendran, TG Gesner, RA Mufson
Journal: Blood
Blood (1990) 76 (2): 290–297.
https://doi.org/10.1182/blood.V76.2.290.290
Published: 1990